Counting the costs: Comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa

Jennifer Smit¹^,2^,3 , Andrew Gray² , Lynn McFadyen¹^,2^,3 and Khangelani Zuma⁴

¹Africa Centre for Population Studies and Reproductive Health, Mtubatuba, South Africa

²Pharmaceutical Policy Practice Group, School of Pharmacy and Pharmacology, University of Durban-Westville, Durban, South Africa

³Division of HIV Prevention and Vaccine Research, South African Medical Research Council, Durban, South Africa

⁴Biostatistics Unit, South African Medical Research Council, Durban, South Africa

author email corresponding author email

BMC Health Services Research 2001, 1:4doi:10.1186/1472-6963-1-4


Published:	4 June 2001

Abstract

Background

In South Africa, where health care resources are limited, it is important to ensure that drugs provision and use is rational. The Essential Drug List includes depot medroxyprogesterone acetate (DMPA) and norethisterone oenanthate (NET-EN) as injectable progestagen-only contraceptives (IPCs), and both products are extensively used.

Objectives and Methods

Utilisation patterns of the injectable contraceptive products DMPA and NET-EN are compared in the context of current knowledge of the safety and efficacy of these agents. Utilisation patterns were analysed by means of a Pareto (ABC) analysis of IPCs issued from 4 South African provincial pharmaceutical depots over 3 financial years. A case study from rural KwaZulu-Natal, South Africa, is used to examine utilisation patterns and self-reported side effects experienced by 187 women using IPCs.

Results

IPCs accounted for a substantial share of total state expenditure on drugs. While more DMPA than NET-EN was issued, NET-EN distribution from 2 depots increased over the 3-year period. Since DMPA was cheaper, if all NET-EN clients in the 1999/2000 financial year (annualised) had used DMPA, the 4 depots could have saved 4.95 million South African Rands on product acquisition costs alone. The KZN case study showed slightly more NET-EN (54%) than DMPA (46%) use; no significant differences in self-reported side effects; and that younger women were more likely to use NET-EN than DMPA (p = 0.0001).

Conclusions

Providing IPCs on the basis of age is not appropriate or cost effective. Rational use of these products should include consideration of the cost of prescribing one over another.